Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: ARPC1B promotes mesenchymal phenotype maintenance and radiotherapy resistance by blocking TRIM21-mediated degradation of IFI16 and HuR in glioma stem cells

Fig. 1

ARPC1B is significantly associated with the MES phenotype and predicts a poor outcome of GBM. A Kaplan–Meier curves revealing overall survival of TCGA-GBM patients stratified in accordance with ARPs’ expression. B The expression of ARPC1B in normal control and GBM tissues (left panel) and the expression of ARPC1B in mesenchymal (MES), proneural (PN), and classical (CL) phenotypes (right panel) in TCGA GBM. C Western blotting of ARPC1B expression in NPCs, MES-GSCs (GSC 20, GSC 267, and GSC 28) and PN-GSCs (GSC 8-11 and GSC 11). D Single-cell RNA sequencing of GSE138794 visualizing UMAP cell clusters, Verhaak_GBM_MES score and ARPC1B expression. E The correlation of ARPC1B expression with PN-associated (DLL3, OLIG2, ASCL1, NCAM1, and SOX2) and MES-associated genes (CD44, FN1, LYN, CHI3L1, and SERPINE1). F Western blot analysis of ARPC1B, CD44 and YKL-40 protein expression upon ARCP1B knockdown in GSCs. β-Actin served as the control

Back to article page